← Leaderboards
Eugene Roussel
Bioprovar Corporation
$1,237,146
Attributed
$1,237,146
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $640K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,237,146 · 2
By mechanism
U44$837,532 · 1
R43$399,614 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Molecular”
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,360,557
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$109,548,439
- Leonard Freedmand · Leidos Biomedical Research, Inc.$85,594,314
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Scott Hensley · University Of Pennsylvania$41,662,743
Research focus
MolecularMonoclonal AntibodiesImmunotherapyMacrophageInflammation MediatorsInnovationComplexElderlyImmune ResponseLigandsCellsInflammationAmericanInflammatoryAnimal ModelBindingBiologicalCytokineExperimental StudyBloodBlood PlateletsFundingAntibodiesMyeloid Cells
Grant awards (4)
An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients$461,487
U44 · FY2025 · AG · contact PI
An Innovative Immune Therapy Targeting the TREM1-Inflammation Pathway to Alleviate Excess Inflammation in Ulcerative Colitis of Geriatric Patients$178,503
R43 · FY2025 · AG · contact PI
An Innovative Immune Therapy Targeting the TREM1-Inflammation Pathway to Alleviate Excess Inflammation in Ulcerative Colitis of Geriatric Patients$221,111
R43 · FY2024 · AG · contact PI
An Innovative Immune Therapy with Antibiotics to Treat Deadly Excess Inflammation in Sepsis and ARDS Induced from Severe Bacterial Infection in Geriatric Patients$376,045
U44 · FY2021 · AG · contact PI